Hill-Rom (NYSE:HRC) was upgraded by analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday.
Several other research analysts have also issued reports on HRC. Zacks Investment Research upgraded Hill-Rom from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. KeyCorp reiterated a “buy” rating and set a $82.00 price objective on shares of Hill-Rom in a research note on Tuesday, October 17th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research note on Saturday, November 4th. Needham & Company LLC dropped their price objective on Hill-Rom from $93.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Finally, Stifel Nicolaus increased their price objective on Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Hill-Rom has a consensus rating of “Hold” and an average target price of $90.29.
Hill-Rom (HRC) opened at $84.64 on Wednesday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. Hill-Rom has a 12 month low of $55.04 and a 12 month high of $85.74. The stock has a market capitalization of $5,548.05, a price-to-earnings ratio of 42.53, a price-to-earnings-growth ratio of 1.81 and a beta of 1.19.
In related news, CEO John J. Greisch sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total value of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares in the company, valued at $19,119,079.82. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the transaction, the chief executive officer now owns 280,851 shares in the company, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. Insiders have sold 226,241 shares of company stock worth $18,708,644 in the last 90 days. Company insiders own 2.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of HRC. Seven Eight Capital LP bought a new position in Hill-Rom in the second quarter valued at about $127,000. Acrospire Investment Management LLC boosted its holdings in Hill-Rom by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after acquiring an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Hill-Rom by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 204 shares during the last quarter. Citigroup Inc. boosted its holdings in Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after acquiring an additional 433 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after acquiring an additional 1,367 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.
WARNING: This report was first posted by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/03/hill-rom-hrc-raised-to-outperform-at-raymond-james-financial.html.
About Hill-Rom
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
